4-MeO-DiPT

4-MeO-DiPT, also known as 4-methoxy-N,N-diisopropyltryptamine, is a novel serotonin receptor modulator of the tryptamine family related to known psychedelic tryptamines like psilocin (4-HO-DMT) and 5-MeO-DMT. It is the 4-methoxy analog of DiPT and the O-methyl ether of 4-HO-DiPT. Very little data exists about the human use, metabolism, and toxicity of 4-MeO-DiPT. "The 5-MeO-DMT has already been mentioned, and the remaining two would be 4-MeO-DMT and 4-MeO-DIPT. The former is a known compound but has not been measured in man. The latter is not a known compound."

Use and effects 4-MeO-DiPT is not known to have been assessed in humans. It is unknown whether the drug produces psychedelic effects in humans.

Interactions

Pharmacology Pharmacodynamics + Target Affinity (Ki, nM) 5-HT1A 2,830–3, (Ki)1,930–3,029 ()94–113% () 5-HT2A 500 (Ki)109–870a ()92a–97% () 5-HT2B 21 ()101% () 5-HT2C 833 (Ki)113–179a ()85a-103% () SERT 12 (Ki)11–17 ()9,844>10,000 Notes: The smaller the value, the more avidly the drug interacts with the site. Footnotes: a = Stimulation of formation. Sources:

4-MeO-DiPT acts as a serotonin reuptake inhibitor and non-selective serotonin receptor agonist, including of the serotonin 5-HT2A, and 5-HT2C receptors. It shows the highest potency as a serotonin reuptake inhibitor with 40- to 50-fold selectivity for the serotonin transporter (SERT) over the 5-HT2A receptor, moderate potency as an agonist of the 5-HT2C receptor, and low potency with high efficacy as an agonist of the 5-HT1A receptor. Affinities towards receptors outside of the serotonin receptor family have not yet been assessed.

Increased extracellular concentrations of serotonin, resulting from SERT blockade, similarly to 4-MeO-MiPT may compete at 5-HT2A, altering or blunting effects mediated by this receptor. This profile makes 4-MeO-DiPT a potential candidate for elucidating the role of SERT blockade in the mechanisms underlying serotonergic psychedelic action.

Chemistry 4-MeO-DiPT is a synthetic derivative of the substituted tryptamine and 4-methoxytryptamine families. It is the 4-methoxy analogue of N,N-diisopropyltryptamine (DiPT) and the O-methyl ether of 4-HO-DiPT.

Analogues Analogues of 4-MeO-DiPT include N,N-diisopropyltryptamine (DiPT), 4-methoxytryptamine (4-MeO-T), 4-MeO-MiPT, 4-MeO-DMT, 4-HO-DiPT, 4-AcO-DiPT, 5-MeO-DiPT, 5-MeO-DMT, and psilocin (4-HO-DMT), among others.

History 4-MeO-DiPT was briefly mentioned by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known Loved). Subsequently, it was described and studied further in the early 2020s.

Society and culture Legal status United States 4-MeO-DiPT is not an explicitly controlled substance in the United States, but may be considered a Schedule I controlled substance in this country as it is a positional isomer of 5-MeO-DiPT.

4-MeO-DiPT

Bron en licentie